Mirum Pharmaceuticals (MIRM) Cash from Financing Activities (2019 - 2026)

Mirum Pharmaceuticals has reported Cash from Financing Activities for 8 years, with the latest figure at $270.1 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities rose 4147.19% year-over-year to $270.1 million; the trailing twelve-month figure through Mar 2026 stood at $303.9 million (up 1229.64% YoY), and the FY2025 full-year result was $40.1 million, up 126.8% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $270.1 million, up from $9.0 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $270.1 million in Q1 2026, with the low at -$329000.0 in Q4 2022.
• Average Cash from Financing Activities over 5 years is $45.5 million, with a median of $8.7 million recorded in 2025.
• Peak annual rise in Cash from Financing Activities reached 24846.67% in 2022, while the deepest fall reached 153.5% in 2022.
• Tracing MIRM's Cash from Financing Activities over 5 years: stood at -$329000.0 in 2022, then jumped by 640.12% to $1.8 million in 2023, then surged by 200.51% to $5.3 million in 2024, then soared by 68.52% to $9.0 million in 2025, then soared by 2901.21% to $270.1 million in 2026.
• The last three Cash from Financing Activities figures came in at $270.1 million (Q1 2026), $9.0 million (Q4 2025), and $16.1 million (Q3 2025), per Business Quant data.

Peer Comparison